Reports Q3 revenue $9.6B, consensus $8.97B. “We delivered strong volume growth this quarter, reflecting the demand for our medicines and the impact we’re having on patients worldwide. With disciplined investment and a pipeline of first-in-class medicines, we’re focused on expanding access, advancing innovation, and sustaining long-term growth,” said Robert Bradway, chairman and chief executive officer.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Notable companies reporting after market close
- These Are the Stocks Reporting Earnings Today – November 4, 2025
- Closing Bell Movers: Palantir down 3% after earnings
- AMGN Earnings this Week: How Will it Perform?
- Amgen’s Promising Phase 3 Study on Blinatumomab for Leukemia: What Investors Need to Know